title: The global cell therapy industry continues to rise during the second and third quarters of 2012.
abstract: During Q2-Q3 2012, the cell therapy industry benefited from a number of positive external influences including advantageous changes to future FDA regulation, but stock market activity was highly mixed. The FDA approved two more products and an appreciable number of public-company-sponsored clinical trials are progressing through phases 1-3.
authors.affiliation: The Advanced Centre for Biochemical Engineering, University College London, Torrington Place, London, WC1E 6BT, UK. chris.mason@ucl.ac.uk
authors.forename: Chris
authors.initials: C
authors.lastname: Mason
authors.forename: Mark J
authors.initials: MJ
authors.lastname: McCall
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Culme-Seymour
authors.forename: Shalini
authors.initials: S
authors.lastname: Suthasan
authors.forename: Simon
authors.initials: S
authors.lastname: Edwards-Parton
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Bonfiglio
authors.forename: Brock C
authors.initials: BC
authors.lastname: Reeve
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000191:economics*; D002986:Clinical Trials as Topic / Q000191:economics / Q000331:legislation & jurisprudence; D003132:Commerce / Q000191:economics; D004345:Drug Industry / Q000191:economics* / Q000331:legislation & jurisprudence; D006801:Humans; D038622:Internationality; D007878:Legislation as Topic; D044968:Regenerative Medicine / Q000191:economics / Q000331:legislation & jurisprudence; D012109:Research Support as Topic / Q000191:economics; D006113:United Kingdom; D014481:United States; D059030:United States Department of Defense